Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type
Author(s): George D Dangas Added: 2 years ago
Dr George Dangas (Mount Sinai Hospital, New York, NY, US) discusses the results of the TWILIGHT-Stent trial, presented at ESC 2021. This study examined the incidence of ischemic and bleeding events in patients treated with contemporary drug-eluting stents over 3-15 months. This trial also examined ticagrelor monotherapy vs ticagrelor with aspirin. Questions: 1. What were the main aims of… View more

Anticoagulation

Intervention
Author(s): Neville Kukreja , Patrick W Serruys Added: 3 years ago
In 2002–2003, drug-eluting stents (DES) were approved by regulatory bodies in Europe and the USA after initial studies showed a dramatic reduction in rates of restenosis compared with bare metal stents (BMS). Subsequent randomized trials in more challenging lesions have confirmed this benefit with a reduction in restenosis of 60–80%, irrespective of the type of lesion or clinical syndrome… View more

Intervention
Author(s): Gaku Nakazawa , Aloke V Finn , Renu Virmani Added: 3 years ago
Polymer-based sirolimus (Cypher®) and paclitaxel (Taxus®) drug-eluting stents (DES) have reduced rates of restenosis and target lesion revascularization (TLR) compared with bare-metal stents (BMS) and have launched a revolution in the interventional treatment of symptomatic coronary artery disease.1,2 However, this overwhelming enthusiasm has recently been dampened by safety concerns regarding a… View more

Anticoagulation

Intervention
History of CV Intervention, Stent Research, GICS & KAMIR in Korea
Author(s): Myung Ho Jeong , Bill D Gogas Added: 3 years ago
In this first episode of Leading Cath & Translational Labs, Prof Myung Ho Jeong, Director of Korea, Cardiovascular Stent Research Institute and Cardiovascular Convergence Research Center, Korea introduces the work of the Kye Hun Kim’s Lab located at Chonnam National University Hospital, Gwangju. View more

Intervention
Consequences and Management of Excessive Ostial Stent Protrusion
Author(s): Arditya Damarkusuma Added: 1 month ago
In this video, Dr Arditya Damarkusuma (Universitas Gadjah Mada, ID) presents his case report on aorto-ostial lesions, recently published in ICR Journal.This case covers the restenosis of a markedly protruding stent at the right coronary ostium in a 54-year old man, and is unusual in its 10-year longevity. Intravascular ultrasound-guided in-stent restenosis intervention using a wire bumper… View more

Imaging & Diagnostics

Intervention
Author(s): David Holmes Jr Added: 3 years ago
Percutaneous coronary revascularization has revolutionized modern cardiovascular care. It has become one of the most well-studied and frequently performed procedures in modern medicine and is currently performed in more than 900,000 patients per year, exceeding the rate of coronary bypass surgery. It is used in an increasingly large number of patient subsets and used to treat an increasingly… View more

Intervention
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 5 months ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
Author(s): Steve Attanasio , Raed Al Dallow , Sandeep Nathan Added: 3 years ago
While acute coronary syndromes inclusive of ST-elevation myocardial infarction (STEMI) have been described in patients with polycythemia vera (PCV), optimal pharmacologic and interventional management strategies in the setting of drastically elevated platelet counts remain unclear.1 To our knowledge this is the first reported case of STEMI with massive thrombus burden in a patient with PCV… View more

MI/ACS
Author(s): Giora Weisz Added: 3 years ago
Much has been written, but little is known, about the long-term outcomes after drug-eluting stent (DES). The introduction of DES has extended the use of stents from a passive platform for vessel wall scaffolding to an active biotechnology vehicle for local delivery of antiproliferative pharmacotherapy. Like any other therapy or medical technology, no treatment is perfect and free of potential… View more

Intervention
Author(s): Peter J Fitzgerald , Martin B Leon Added: 3 years ago
An unintended consequence of the market success of drug-eluting stents has been a growing concern about their safety and safety-related costs. These devices have been so quickly and widely adopted that their market penetration already equals that of some of the most popular pharmaceutical drugs. Consequently, the absolute significance of even a low incidence of side effects becomes magnified by… View more

Intervention